Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IN001 mRNA Vaccine in Healthy Participants 50 to 69 Years Old
NCT06375512Phase 1Completed
- Sponsor
- Shenzhen Shenxin Biotechnology Co., Ltd.
- Start
- Jul 2024
- Primary completion
- Feb 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of IN001 in herpes zoster (HZ) (5 arms), sponsored by Shenzhen Shenxin Biotechnology Co., Ltd. Primary endpoints: Percentage of Participants Reporting Solicited Local Reactions, Percentage of Participants Reporting Solicited Systemic Reactions and 3 more. Started Jul 2024; status: completed.
02
Drugs
IN001
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT06375512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06375512.